News

What to know about new COVID variant discovered in US. Check out NB 1.8.1 symptoms
A new COVID variant - NB 1.8.1 - is creeping across the country; here are the symptoms to watch for, and vaccinations you'll ...
New COVID variant spreads in California. What are the COVID NB 1.8.1. symptoms?
A new COVID variant, NB 1.8.1, is being detected across California; here are the symptoms to watch for, and vaccinations ...
Despite trade war, US drug companies turn to China for key cancer treatments
US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio?
BMY teams with BioNTech on BNT327, a dual-target cancer therapy, as legacy drugs face mounting generic pressure ...
Truist Financial Sticks to Its Buy Rating for Exelixis (EXEL)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed yesterday at $ ...
Fierce Pharma1d
Fierce Pharma Asia—Bispecific field's roller coaster week; Enhertu's first-line win; Regeneron-Hansoh obesity deal
The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...
Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment
Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...
Medical Dialogues1d
Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types
Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...
Investing Snacks1d
BioNTech + Bristol = Cancer’s Worst Nightmare
Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.